title: Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
abstract: HIV-infected patients remain at higher risk for pneumococcal disease than the general population despite immune reconstitution and suppression of HIV replication with combination antiretroviral therapy. Vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) composed of T-cell-independent antigens has been recommended to reduce the risk of pneumococcal disease in HIV-infected adults. However, given the heterogeneity of study design, execution and subjects enrolled, studies examining serological responses to PPV23 yielded conflicting results and observational studies of clinical effectiveness only provided moderate evidence to support the routine use of PPV23 in HIV-infected adults. Pneumococcal conjugate vaccine (PCV), with conjugation of the capsular polysaccharide to a protein carrier, is more immunogenic than PPV23 and has been demonstrated to protect against pneumococcal disease in HIV-infected children and recurrent invasive pneumococcal disease in HIV-infected adolescents and adults. Guidelines have recently been revised to recommend that HIV-infected patients aged 19 y or older receive one dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed by a booster vaccination with PPV23. In this paper, we review the studies using different vaccination strategies to improve immunogenicity among HIV-infected adult patients.
authors.affiliation: a Department of Internal Medicine ; National Taiwan University Hospital; Hsin-Chu Branch ; Hsin-Chu , Taiwan.
authors.forename: Kuan-Yeh
authors.initials: KY
authors.lastname: Lee
authors.forename: Mao-Song
authors.initials: MS
authors.lastname: Tsai
authors.forename: Kuang-Che
authors.initials: KC
authors.lastname: Kuo
authors.forename: Jen-Chih
authors.initials: JC
authors.lastname: Tsai
authors.forename: Hsin-Yun
authors.initials: HY
authors.lastname: Sun
authors.forename: Aristine C
authors.initials: AC
authors.lastname: Cheng
authors.forename: Sui-Yuan
authors.initials: SY
authors.lastname: Chang
authors.forename: Chen-Hsiang
authors.initials: CH
authors.lastname: Lee
authors.forename: Chien-Ching
authors.initials: CC
authors.lastname: Hung
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D022242:Pneumococcal Vaccines / Q000276:immunology*; D017410:Practice Guidelines as Topic; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000276:immunology; D014779:Virus Replication
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D019380:Anti-HIV Agents; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
keywords: ACIP, Advisory Committee on Immunization Practices; AIDS; ART, antiretroviral therapy; DHHS, Department of Health and Human Services; EACS, European AIDS Clinical Society; ELISA, enzyme-linked immunosorbent assay; GMT, geometric mean titer; IPD, invasive pneumococcal disease; NA, not available; OPA, opsonophagocytic activity; PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vccine; PPV, pneumococcal polysaccharide vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; PVL, plasma HIV RNA load; Streptococcus pneumoniae; TLR, toll-like receptor; cART, combination antiretroviral therapy; immunodeficiency; immunogenicity; invasive pneumococcal disease; pneumococcal conjugate vaccine; pneumococcal disease; pneumococcal polysaccharide vaccine